Freundlich Pharma (India) Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
- Paid Up Capital ₹ 0.50 M
- Company Age 26 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.03 Cr
- Revenue Growth %
- Ebitda
- Net Worth 100.09%
- Total Assets -99.17%
About Freundlich Pharma (India)
Company Details
-
Location
Pune, Maharashtra, India
-
Telephone
+91-XXXXXXXXXX
- Email Address
-
Website
-
-
Social Media
-
Corporate Identity Details
-
CIN/LLPIN
U24232PN1998PTC013109
-
Company No.
013109
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
10 Dec 1998
-
Date of AGM
15 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Pune
Industry
Who are the key members and board of directors at Freundlich Pharma (India)?
Board Members (2)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Ranjana Sahastrabudhe
![]() |
Director | 10-Dec-1998 | Current |
Ajit Sahasrabudhe
![]() |
Director | 10-Dec-1998 | Current |
Financial Performance of Freundlich Pharma (India).
Freundlich Pharma (India) Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth Soared by an impressive increase of 100.09%.
![Graph illustrating revenue growth over time](/Images/financial/revenue-growth.webp)
![Graph showing profit and loss trends over time](/Images/financial/profit-loss.webp)
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
|
||||||
Revenue from Operations |
|
||||||
Total Assets |
|
||||||
Profit or Loss |
|
||||||
Net Worth |
|
||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Freundlich Pharma (India)?
In 2023, Freundlich Pharma (India) had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
![Shareholding Indicator graph](/Images/tcc-login/Shareholding-Indiacator-1200.webp)
Charges (Loans)
₹0
₹10.34 M
Charges Breakdown by Lending Institutions
- Shree Suvarna Sahakari Bank Ltd : 0.75 Cr
- The Shree Suvarna Sahakari Bank Ltd : 0.28 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
20 Mar 2001 | Shree Suvarna Sahakari Bank Ltd | ₹7.50 M | Satisfied |
03 Dec 1999 | The Shree Suvarna Sahakari Bank Ltd | ₹2.80 M | Satisfied |
06 Nov 1999 | The Shree Suvarna Sahakari Bank Ltd | ₹0.04 M | Satisfied |
How Many Employees Work at Freundlich Pharma (India)?
Unlock and access historical data on people associated with Freundlich Pharma (India), such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
![Graph showing employee growth trends](/Images/tcc-login/Employee-Graph.webp)
Deals i
![Graph showing company valuation over time](/Images/tcc-login/Valuation-Graph-small.webp)
Gain comprehensive insights into the Deals and Valuation data of Freundlich Pharma (India), offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Freundlich Pharma (India)'s trajectory.
Rating
![Graph displaying rating trends over time](/Images/tcc-login/Rating-Graph-small.webp)
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
![Alert Indicator](/Images/tcc-login/Alert-Indicator-small.webp)
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.